These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30834780)

  • 1. Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies.
    Harbeck N; Wang J; Otto GP; Gattu S; Krendyukov A
    Future Oncol; 2019 Apr; 15(12):1313-1322. PubMed ID: 30834780
    [No Abstract]   [Full Text] [Related]  

  • 2. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
    Blackwell K; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Harbeck N
    Ann Oncol; 2017 Sep; 28(9):2272-2277. PubMed ID: 28637287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
    Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
    BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
    Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
    Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K; Gascon P; Krendyukov A; Gattu S; Li Y; Harbeck N
    Ann Oncol; 2018 Jan; 29(1):244-249. PubMed ID: 29091995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
    Waller CF; Ranganna GM; Pennella EJ; Blakeley C; Bronchud MH; Mattano LA; Berzoy O; Voitko N; Shparyk Y; Lytvyn I; Rusyn A; Popov V; Láng I; Beckmann K; Sharma R; Baczkowski M; Kothekar M; Barve A
    Ann Hematol; 2019 May; 98(5):1217-1224. PubMed ID: 30824956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LA-EP2006: A Pegfilgrastim Biosimilar.
    Hoy SM
    BioDrugs; 2019 Apr; 33(2):229-232. PubMed ID: 30887256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
    Botteri E; Krendyukov A; Curigliano G
    Eur J Cancer; 2018 Jan; 89():49-55. PubMed ID: 29227817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
    Harbeck N; Gascón P; Krendyukov A; Hoebel N; Gattu S; Blackwell K
    Oncologist; 2018 Apr; 23(4):403-409. PubMed ID: 29317553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.
    Harbeck N; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Blackwell K
    Future Oncol; 2017 Jul; 13(16):1385-1393. PubMed ID: 28453299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
    Waller CF; Tiessen RG; Lawrence TE; Shaw A; Liu MS; Sharma R; Baczkowski M; Kothekar MA; Micales CE; Barve A; Ranganna GM; Pennella EJ
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1087-1095. PubMed ID: 29671069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the Treatment of Chemotherapy-induced Febrile Neutropenia and Current Updates on Clinical Trials.
    Ali F; Sharma K; Ali A
    Curr Drug Targets; 2022; 23(9):924-932. PubMed ID: 35400340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
    Park KH; Sohn JH; Lee S; Park JH; Kang SY; Kim HY; Park IH; Park YH; Im YH; Lee HJ; Hong DS; Park S; Shin SH; Kwon HC; Seo JH
    Invest New Drugs; 2013 Oct; 31(5):1300-6. PubMed ID: 23677653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients.
    Pawloski PA; Larsen M; Thoresen A; Giordana MD
    J Oncol Pharm Pract; 2016 Jun; 22(3):423-9. PubMed ID: 25956422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
    Park KH; Lee S; Park JH; Kang SY; Kim HY; Park IH; Park YH; Im YH; Lee HJ; Park S; Lee SI; Jung KH; Kim YS; Seo JH
    Support Care Cancer; 2017 Feb; 25(2):505-511. PubMed ID: 27709313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RGB-02 (biosimilar pegfilgrastim) in the treatment of chemotherapy-induced neutropenia.
    Sántha D; Illés A; Aradi I; Horvát-Karajz K; Kahán Z
    Future Oncol; 2019 Jun; 15(18):2083-2092. PubMed ID: 31210542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure.
    Cornes P; Gascon P; Vulto AG; Aapro M
    BioDrugs; 2020 Jun; 34(3):255-263. PubMed ID: 32232676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.
    Hoy SM
    BioDrugs; 2019 Feb; 33(1):117-120. PubMed ID: 30701419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
    McBride A; Campbell K; Bikkina M; MacDonald K; Abraham I; Balu S
    J Med Econ; 2017 Oct; 20(10):1083-1093. PubMed ID: 28722494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.